Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alprazolam + fluoxetine
- Development stage
- Unknown
- Lead developer
- Charan Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CFA-20 is a fixed-dose combination of alprazolam and fluoxetine hydrochloride, developed and marketed by Charan Laboratories. Alprazolam is a short-acting benzodiazepine that acts as a positive allosteric modulator of the GABA-A receptor, enhancing GABAergic transmission to provide rapid anxiolytic effects. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter (SERT), increasing synaptic serotonin levels to treat depressive symptoms. This combination is indicated for the treatment of major depressive disorder (MDD) accompanied by moderate to severe anxiety, where the rapid onset of alprazolam helps manage acute anxiety symptoms while fluoxetine achieves therapeutic levels.
- Brand names
- AltinAlzonex PlusCFA-20CFA20CFA 20Calmsac PlusCozac AzDeplam FExiten PlusFaa PlusFax AFaxtin AFloxin PlusFlumusa ForteFluwelFluxozamFluxy-ANoten-FXRelax FTizadepZedep AZexto PlusZomark FX
- Other names
- alprazolam + fluoxetine hydrochloridefluoxetine + alprazolam
02
Targets
DAT (Dopamine plasma membrane transport protein)BZD site (GABA-A receptor benzodiazepine site)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)GABAA (Gamma-aminobutyric acid receptor)
Beyond the preview
Go deeper on alprazolam + fluoxetine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alprazolam + fluoxetine.